HUP0303754A2 - Gyökfogó vegyületek alkalmazása NO-függő mikrokeringési zavarok kezelésére és megelőzésére szolgáló gyógyszerkészítmény előállítására - Google Patents

Gyökfogó vegyületek alkalmazása NO-függő mikrokeringési zavarok kezelésére és megelőzésére szolgáló gyógyszerkészítmény előállítására

Info

Publication number
HUP0303754A2
HUP0303754A2 HU0303754A HUP0303754A HUP0303754A2 HU P0303754 A2 HUP0303754 A2 HU P0303754A2 HU 0303754 A HU0303754 A HU 0303754A HU P0303754 A HUP0303754 A HU P0303754A HU P0303754 A2 HUP0303754 A2 HU P0303754A2
Authority
HU
Hungary
Prior art keywords
microcirculation disorders
treatment
pharmaceutical
compsoition
prevention
Prior art date
Application number
HU0303754A
Other languages
English (en)
Inventor
Wolfgang Eisert
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of HUP0303754A2 publication Critical patent/HUP0303754A2/hu
Publication of HUP0303754A3 publication Critical patent/HUP0303754A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgya eljárás a humán vagy nemhumán állati test NO-függőmikrokeringési zavarainak, így a metabolikus betegségek által,gyulladásos reakciók által, autoimmun betegségek által okozottmikrokeringési zavarok, valamint a perifériás mikrokeringési zavarok,a megnövekedett sejtfragmentációval kapcsolatos mikrokeringési zavarokkezelésére; amely eljárás abból áll, hogy az ilyen kezelésreszorulónak egy szabad gyököket befogadó anyagot, így dipyridamol vagymopidamol és gyógyszerészetileg elfogadható sóik közül választottpirimido-pirimidinszármazékot, adott esetben az NO-képződésneknövelésére képes szerrel kombináltan tartalmazó gyógyszerkészítményhatásos adagját adják be. A találmány kiterjed a fenti hatóanyagottartalmazó gyógyszerkészítmény előállítására is. Ó
HU0303754A 2001-04-20 2002-04-13 Use of radical scavenging compounds for preparation of pharmaceutical compsoition suitable for treatment and prevention of no-dependent microcirculation disorders HUP0303754A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119680A DE10119680A1 (de) 2001-04-20 2001-04-20 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
PCT/EP2002/004129 WO2002085368A2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders

Publications (2)

Publication Number Publication Date
HUP0303754A2 true HUP0303754A2 (hu) 2004-03-01
HUP0303754A3 HUP0303754A3 (en) 2006-02-28

Family

ID=7682292

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303754A HUP0303754A3 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for preparation of pharmaceutical compsoition suitable for treatment and prevention of no-dependent microcirculation disorders

Country Status (10)

Country Link
EP (1) EP1389112A2 (hu)
JP (1) JP2004525979A (hu)
AU (1) AU2002338396B2 (hu)
CA (1) CA2444370A1 (hu)
DE (1) DE10119680A1 (hu)
HU (1) HUP0303754A3 (hu)
IL (1) IL158091A0 (hu)
MX (1) MXPA03009506A (hu)
NZ (1) NZ529115A (hu)
WO (1) WO2002085368A2 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329930T3 (es) * 2005-02-11 2009-12-02 Nolabs Ab Dispositivo, metodo y uso para el tratamiento de la neuropatia con oxido nitrico.
MD4341C1 (ro) * 2013-11-21 2015-11-30 Ион МЕРЕУЦЭ Sirop pentru tratamentul stărilor precanceroase gastrice
EP3250201A4 (en) * 2015-01-28 2018-08-01 Realinn Life Science Limited Compounds for enhancing ppar expression and nuclear translocation and therapeutic use thereof
CN113244395A (zh) * 2020-02-10 2021-08-13 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1711892A1 (ru) * 1989-01-06 1992-02-15 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени диабетической ангиопатии
SU1711894A1 (ru) * 1989-08-08 1992-02-15 Детская Клиническая Больница N1 Способ лечени декомпенсированных форм стенозирующего ларинготрахеита у детей
IT1239064B (it) * 1990-05-14 1993-09-20 Fidia Spa Uso terapeutico del dipiridamolo
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
AU7397094A (en) * 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Also Published As

Publication number Publication date
MXPA03009506A (es) 2004-02-12
CA2444370A1 (en) 2002-10-31
JP2004525979A (ja) 2004-08-26
IL158091A0 (en) 2004-03-28
WO2002085368A2 (en) 2002-10-31
HUP0303754A3 (en) 2006-02-28
AU2002338396B2 (en) 2007-10-18
DE10119680A1 (de) 2002-11-14
EP1389112A2 (en) 2004-02-18
NZ529115A (en) 2005-08-26
WO2002085368A3 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
CN104662007B (zh) 胱硫醚‑γ‑裂合酶(CSE)抑制剂
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
JPH0144684B2 (hu)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
US20130059888A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
SE9901573D0 (sv) New compounds
ES2635353T3 (es) Formas de dosificación y usos terapéuticos de la L-4-cloroquinurenina
RU2104032C1 (ru) Способ усиления лечебного эффекта лекарственных средств
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JPH06505014A (ja) 抗ストレス、ストレス予防性及び向神経性作用の医薬調製物
ZA200105275B (en) New use of melagatran.
HUP0303754A2 (hu) Gyökfogó vegyületek alkalmazása NO-függő mikrokeringési zavarok kezelésére és megelőzésére szolgáló gyógyszerkészítmény előállítására
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
JPH0651669B2 (ja) 抗炎症及び鎮痛活性を有する化合物及び組成物
JP2005513105A5 (hu)
JP2000500159A (ja) メラトニンと組み合わせた鎮痛剤
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
AU777223B2 (en) Medicaments
US3686409A (en) Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees